Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CryoCor a-fib trial

This article was originally published in The Gray Sheet

Executive Summary

The San Diego firm completes enrollment for pivotal clinical trial studying treatment of atrial fibrillation with its CryoCor cryoablation system Aug. 27. The system treats cardiac arrhythmias with cryonenergy, or extreme cold, to destroy targeted cardiac tissue. CryoCor has enrolled over 170 patients in the pivotal study and will conduct a 12-month follow-up for each patient. The company obtained FDA approval to market the device to treat atrial flutter in August and expects to receive approval for the atrial fibrillation indication in 2009. CryoCor is one of a handful of firms with ablation devices aiming to be the first to market with a-fib labeling...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts